UK and India regulators agree deal for closer collaboration to improve public safety

5 October 2015

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today signed a Memorandum of Understanding (MoU) with its counterpart body in India. This agreement will increase collaboration between the two countries in the area of medicines and medical devices with the aim of further improving public safety in both countries.

This is the first MoU agreed with the Central Drugs Standard Control Organization (CDSCO), part of the Ministry of Health and Family Welfare of Republic of India, and was signed by Dr Gyandedra Nath Singh, India’s Drugs Controller General, and MHRA chairman, Professor Sir Michael Rawlins. It provides a formal agreement between the two organizations, and strengthens relations between the UK and Indian governments.

Exchange of information and opportunities for technical cooperation

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK